Jasper Therapeutics Q2 2023 net loss $16.1M; cash $115.8M; first patient dosed in LR-MDS trial

Jasper Therapeutics, Inc.

2023-Q2 EPS reported -$0.31

Net loss of $16.1M for Q2 2023 vs $10.4M in Q2 2022; R&D expenses increased to $13.3M from $8.1M.
Cash and cash equivalents $115.8M as of June 30, 2023, up from $38.3M at Dec 31, 2022; runway through 2024.
First patient dosed in Phase 1 trial of briquilimab for lower-risk MDS (LR-MDS) at Moffitt Cancer Center.
Key appointments: Scott Brun to Board, Edwin Tucker as CMO, and others to Scientific Advisory Board and leadership.
Company plans to initiate chronic spontaneous urticaria study in coming months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jasper Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net Loss: For the quarter ended June 30, 2023, net loss was $16.1 million compared to net loss of $10.4 million for the.

Period: the quarter ended June 30, 2023
Net income: Net Loss: For the quarter ended June 30, 2023, net loss was $16.1 million compared to net loss of $10.4 million for the
Result: reported results

Exact text from the filing

On August 11, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2023 and providing a business update.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-066233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.